Effect of point-spread function reconstruction for indeterminate PSMA-RADS-3A lesions on PSMA-targeted PET imaging of men with prostate cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Diagnostics (2021) 11:4, 665. https://doi.org/10.3390/diagnostics11040665
- Ereignis
-
Veröffentlichung
- (wo)
-
Würzburg
- (wer)
-
Universität Würzburg
- (wann)
-
2022
- Urheber
-
Khatri, Wajahat
Chung, Hyun Woo
Wolf, Herta
Leal, Jeffrey P.
Pienta, Kenneth J.
Lodge, Martin A.
Gorin, Michael A.
Pomper, Martin G.
Rowe, Steven P.
- DOI
-
10.3390/diagnostics11040665
- URN
-
urn:nbn:de:bvb:20-opus-236528
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:51 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Khatri, Wajahat
- Chung, Hyun Woo
- Wolf, Herta
- Leal, Jeffrey P.
- Pienta, Kenneth J.
- Lodge, Martin A.
- Gorin, Michael A.
- Pomper, Martin G.
- Rowe, Steven P.
- Universität Würzburg
Entstanden
- 2022
Ähnliche Objekte (12)
Follow-up of lesions with equivocal radiotracer uptake on PSMA-targeted PET in patients with prostate cancer: predictive values of the PSMA-RADS-3A and PSMA-RADS-3B categories
Theranostics in oncology — thriving, now more than ever
Matched-pair analysis of [\(^177}\)Lu]Lu-PSMA I&T and [\(^177}\)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Association of true positivity with serum prostate-specific antigen levels and other clinical factors in indeterminate PSMA-RADS-3A lesions identified on \(^18}\)F-DCFPyL PET/CT scans
Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [\(^177}\)Lu]Lu-PSMA I&T
Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [\(^177}\)Lu]Lu-PSMA I&T during long-term follow-up
A Voice From the Past: Re-Discovering the Virchow Node with PSMA-targeted \(^18}\)F-DCFPyL PET Imaging
A Voice From the Past: Re-Discovering the Virchow Node with PSMA-targeted \(^18}\)F-DCFPyL PET Imaging
Changing threshold-based segmentation has no relevant impact on semi-quantification in the context of structured reporting for PSMA-PET/CT
Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on \(^18}\)F-DCFPyL PET/CT Imaging
Interobserver agreement for the standardized reporting system PSMA-RADS 1.0 on 18F-DCFPyL PET/CT imaging
Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted \(^18}\)F-DCFPyL in peripheral ganglia
Follow-up of lesions with equivocal radiotracer uptake on PSMA-targeted PET in patients with prostate cancer: predictive values of the PSMA-RADS-3A and PSMA-RADS-3B categories
Theranostics in oncology — thriving, now more than ever
Matched-pair analysis of [\(^177}\)Lu]Lu-PSMA I&T and [\(^177}\)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Association of true positivity with serum prostate-specific antigen levels and other clinical factors in indeterminate PSMA-RADS-3A lesions identified on \(^18}\)F-DCFPyL PET/CT scans
Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [\(^177}\)Lu]Lu-PSMA I&T
Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [\(^177}\)Lu]Lu-PSMA I&T during long-term follow-up
A Voice From the Past: Re-Discovering the Virchow Node with PSMA-targeted \(^18}\)F-DCFPyL PET Imaging
A Voice From the Past: Re-Discovering the Virchow Node with PSMA-targeted \(^18}\)F-DCFPyL PET Imaging
Changing threshold-based segmentation has no relevant impact on semi-quantification in the context of structured reporting for PSMA-PET/CT
Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on \(^18}\)F-DCFPyL PET/CT Imaging
Interobserver agreement for the standardized reporting system PSMA-RADS 1.0 on 18F-DCFPyL PET/CT imaging
Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted \(^18}\)F-DCFPyL in peripheral ganglia
Follow-up of lesions with equivocal radiotracer uptake on PSMA-targeted PET in patients with prostate cancer: predictive values of the PSMA-RADS-3A and PSMA-RADS-3B categories
Theranostics in oncology — thriving, now more than ever
Matched-pair analysis of [\(^177}\)Lu]Lu-PSMA I&T and [\(^177}\)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Association of true positivity with serum prostate-specific antigen levels and other clinical factors in indeterminate PSMA-RADS-3A lesions identified on \(^18}\)F-DCFPyL PET/CT scans
Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [\(^177}\)Lu]Lu-PSMA I&T
Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [\(^177}\)Lu]Lu-PSMA I&T during long-term follow-up
A Voice From the Past: Re-Discovering the Virchow Node with PSMA-targeted \(^18}\)F-DCFPyL PET Imaging
A Voice From the Past: Re-Discovering the Virchow Node with PSMA-targeted \(^18}\)F-DCFPyL PET Imaging
Changing threshold-based segmentation has no relevant impact on semi-quantification in the context of structured reporting for PSMA-PET/CT
Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on \(^18}\)F-DCFPyL PET/CT Imaging
Interobserver agreement for the standardized reporting system PSMA-RADS 1.0 on 18F-DCFPyL PET/CT imaging